MSH6 and central nervous system cancer: Using this approach, we found that BTICs and xenografts that were intrinsically resistant or became resistant to TMZ through the acquisition of MSH6 mutations were sensitized by co-treatment with ABT-888, but surprisingly, adding ABT-888 to TMZ did not magnify the intrinsic sensitivity of models of newly diagnosed methylated high-grade gliomas.